Neuland Labs declares Q1 FY27 unaudited results, approves ₹40 Cr guarantee

Neuland Laboratories Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors also approved a corporate guarantee of ₹40 crores in favor of Gland Pharma Limited for a Loan Licence Agreement. This agreement is to establish dedicated manufacturing capacity and incur capital expenditure for specific products. The company is also enhancing manufacturing capacity at Unit 1, with an investment of ₹39.8 crores funded through internal accruals, expected to be completed in 6-7 months. The corporate guarantee represents a contingent liability with no immediate impact on financials.